Truist Financial Initiates Coverage on Lumexa Imaging (NASDAQ:LMRI)

Investment analysts at Truist Financial began coverage on shares of Lumexa Imaging (NASDAQ:LMRI) in a report released on Monday, MarketBeat Ratings reports. The firm set a “buy” rating and a $18.00 price target on the stock. Truist Financial’s price target would suggest a potential upside of 68.07% from the company’s previous close.

LMRI has been the topic of a number of other reports. UBS Group reissued a “strong-buy” rating on shares of Lumexa Imaging in a research note on Monday, September 28th. Barclays raised their price target on Lumexa Imaging from $9.00 to $13.00 and gave the stock an “overweight” rating in a research report on Friday, August 28th. Raymond James Financial set a $17.00 price objective on Lumexa Imaging in a research report on Monday, September 28th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Lumexa Imaging in a research note on Tuesday, September 22nd. Finally, KeyCorp began coverage on shares of Lumexa Imaging in a research report on Thursday, September 24th. They set an “overweight” rating and a $18.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Lumexa Imaging presently has an average rating of “Buy” and an average price target of $16.40.

Lumexa Imaging Price Performance

LMRI stock opened at $10.71 on Monday. The business has a 50 day moving average price of $11.29 and a 200 day moving average price of $10.26. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 1.40. Lumexa Imaging has a fifty-two week low of $6.45 and a fifty-two week high of $19.45. The stock has a market cap of $1.03 billion and a price-to-earnings ratio of -21.86.

Lumexa Imaging (NASDAQ:LMRI) last posted its quarterly earnings results on Wednesday, August 12th. The company reported $0.20 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.17. The company had revenue of $264.16 million for the quarter. Lumexa Imaging has set its FY 2026 guidance at 0.710-0.770 EPS. Equities research analysts anticipate that Lumexa Imaging will post 0.25 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Squarepoint Ops LLC lifted its holdings in shares of Lumexa Imaging by 506.9% during the second quarter. Squarepoint Ops LLC now owns 79,934 shares of the company’s stock worth $902,000 after buying an additional 66,763 shares during the last quarter. Readystate Asset Management LP increased its holdings in shares of Lumexa Imaging by 11.5% during the 2nd quarter. Readystate Asset Management LP now owns 250,533 shares of the company’s stock worth $2,826,000 after purchasing an additional 25,778 shares during the period. AXQ Capital LP acquired a new stake in Lumexa Imaging during the second quarter worth about $128,000. Bank of America Corp DE acquired a new position in shares of Lumexa Imaging in the second quarter valued at $200,000. Finally, Jupiter Topco LLC bought a new position in shares of Lumexa Imaging during the 2nd quarter worth about $24,269,000.

Lumexa Imaging Company Profile

Lumexa Imaging, Inc (NASDAQ: LMRI) is a U.S. healthcare services company focused on outpatient diagnostic imaging. The company operates and supports imaging centers that provide noninvasive services used to detect, diagnose and monitor medical conditions.

Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, X-ray and other diagnostic imaging procedures. Lumexa also works with radiologists and referring healthcare providers to deliver image interpretation and related clinical services.

The company’s operations are primarily located in the United States, serving patients through a network of outpatient imaging facilities and affiliated radiology practices.